Nanobiotix S.A. ADR NBTX 深 沪
已收盘 08-22 16:00:00 美东时间
10.0942
+0.357
+3.66%
华盛通- 最 高10.59
- 今 开10.20
- 成交量 4.15万股
- 最 低 9.7742
- 昨 收 9.7374
- 总市值 4.79亿
- 52周最高 10.59
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.76
- 委 比 98.25%
- 总股本 4740.47万
- 历史最高 21.55
- 量 比 1.74
- 振 幅 8.38%
- 历史最低 1.75
- 每 手 1
- 风险率 0.90%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多SelectQuote Posts Better-Than-Expected Results, Joins Nutex Health, NIO, MINISO Group And Other Big Stocks Moving Higher On Thursday
U.S. stocks were lower, with the Dow Jones index falling more than 100 points o...
08-21 23:32
Nanobiotix Advances JNJ-1900 with Regulatory and Patent Milestones
Nanobiotix ( ($NBTX) ) just unveiled an announcement. On July 7, 2025, Nanobiot...
07-12 05:27
Nanobiotix Allocates Free Shares to Executives
An update from Nanobiotix ( ($NBTX) ) is now available. Nanobiotix, a company i...
07-02 23:07
Voting Rights and Shares Capital of the Company
Nanobiotix, a late-stage clinical biotechnology company, announced updates on its share capital and voting rights as of May 31, 2025. The company, listed on Euronext Paris and Nasdaq, reported 47,426,851 outstanding shares and theoretical voting rights totaling 49,529,244, with 49,507,126 exercisable. Nanobiotix, headquartered in Paris, has developed over 25 patent families across three nanotechnology platforms addressing oncology, bioavailabilit...
06-10 20:15
Nanobiotix Sa ADR Reports Q1 2025 Progress
Nanobiotix Sa ADR ( ($NBTX) ) has released its Q1 earnings. Here is a breakdown...
06-06 11:51
NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference
Nanobiotix, a late-clinical stage biotechnology company, announced that its management will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2025, at 3:45 pm EDT. The event will be webcast live and available for replay. Nanobiotix, headquartered in Paris with subsidiaries in Cambridge, Massachusetts, focuses on nanoparticle-based therapies for cancer and other diseases. The company has over 25 patents across...
05-28 06:00
Nanobiotix Provides Q1 2025 Operational Update; Says It Anticipates That The Cash And Cash Equivalents Of €39.8 Million As Of March 31, 2025, Will Fund Its Operations Into Mid-2026
Dosing of a first patient in the CONVERGE study, a Phase 2 randomized controlled clinical trial for patients with stage 3 unresectable non-small cell lung cancerPresentation of data at the European Lung Cancer Conference
05-22 04:18
Nanobiotix to Present at H.C. Wainwright BioConnect Conference
Nanobiotix ( ($NBTX) ) has shared an update. On May 12, 2025, Nanobiotix announ...
05-12 23:57
Nanobiotix Highlights Median 13.3-Month Local Progression-Free Survival With JNJ-1900 (NBTXR3) After Radiation
Results demonstrated favorable safety, injection feasibility, and encouraging oncologic outcomes in patients (n=22) with locally advanced or borderline resectable pancreatic cancerMedian Overall Survival of 23 months
05-05 14:11
Nanobiotix Discloses Managerial Share Acquisitions in April 2025
Nanobiotix ( ($NBTX) ) has issued an announcement. On April 10, 2025, Nanobioti...
04-10 18:47
